UBS Group’s Ocugen OCGN Stock Holding History

UBS Group’s Portfolio OCGN Stock Details OCGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-2,240,300	Closed	-$18M	–	9913
2021 Q2	$18M	Buy	+2,240,300	New	+$18.9M	0.01%	1575

Other funds holding OCGN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return

GMT Capital Atlanta, Georgia $1.92B AUM 70.51% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

UBS Group's OCGN Position: Q2 2026 in Review

UBS Group reduced its Ocugen (OCGN) stake by 29% in Q2 2026, selling an estimated $3.2M and leaving 5,177,508 shares worth $7.92M. The position accounts for ﹤0.01% of the portfolio, ranked #3703.

UBS Group first reported a position in OCGN in Q4 2014 and has held it in 40 quarters since. The position peaked at $13.2M in Q1 2026. 147 funds tracked by Wall St. Rank hold OCGN as of Q2 2026.

UBS Group held 5,177,508 shares of Ocugen worth $7.92M as of Q2 2026.
UBS Group sold 2,102,812 Ocugen shares in Q2 2026, an estimated $3.2M.
Ocugen made up ﹤0.01% of UBS Group's portfolio in Q2 2026, its #3703 holding.
UBS Group first reported a position in Ocugen in Q4 2014 and has held it in 40 quarters since.
UBS Group's Ocugen position peaked at $13.2M in Q1 2026.
147 funds tracked by Wall St. Rank held Ocugen as of Q2 2026.

Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.